Swiss National Bank Immunity Bio, Inc. Transaction History

Swiss National Bank

$150 Billion
Q3 2024

A detailed history of Swiss National Bank transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Swiss National Bank holds 270,000 shares of IBRX stock, worth $710,100. This represents 0.0% of its overall portfolio holdings.

Number of Shares

270,000

Previous 263,100 2.62%

Holding current value

$710,100

Previous $1.66 Million 39.77%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 07, 2024	BUY	$3.32 - $6.7 $22,908 - $46,230	6,900 Added 2.62%	270,000 $1 Million
Q4 2023 Feb 06, 2024	SELL	$1.25 - $5.21 $26,875 - $112,015	-21,500 Reduced 7.55%	263,100 $1.32 Million
Q2 2023 Aug 09, 2023	BUY	$1.53 - $6.41 $38,862 - $162,814	25,400 Added 9.8%	284,600 $791,000
Q1 2023 May 10, 2023	SELL	$1.35 - $4.78 $41,580 - $147,224	-30,800 Reduced 10.62%	259,200 $471,000
Q4 2022 Feb 08, 2023	BUY	$4.35 - $6.77 $38,715 - $60,252	8,900 Added 3.17%	290,000 $1.47 Million
Q2 2022 Aug 09, 2022	BUY	$2.68 - $6.14 $249,508 - $571,634	93,100 Added 49.52%	281,100 $1.05 Million
Q1 2022 May 09, 2022	BUY	$5.05 - $7.53 $80,295 - $119,727	15,900 Added 9.24%	188,000 $1.06 Million
Q4 2021 Feb 08, 2022	BUY	$5.67 - $10.18 $14,175 - $25,450	2,500 Added 1.47%	172,100 $1.05 Million
Q3 2021 Nov 08, 2021	BUY	$9.17 - $14.24 $784,035 - $1.22 Million	85,500 Added 101.66%	169,600 $1.65 Million
Q2 2021 Aug 06, 2021	BUY	$13.41 - $22.4 $128,736 - $215,040	9,600 Added 12.89%	84,100 $1.2 Million
Q1 2021 May 07, 2021	BUY	$12.83 - $42.25 $955,835 - $3.15 Million	74,500 New	74,500 $1.77 Million

Others Institutions Holding IBRX

# of Institutions

204

Shares Held

70M

Call Options Held

1.68M

Put Options Held

1.31M

View Full List

About ImmunityBio, Inc.

Ticker IBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 400,304,000
Market Cap $1.05B
Description
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...

More about IBRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Account

Swiss National Bank Immunity Bio, Inc. Transaction History